top of page

IntraBio Media Release | February 7, 2024

The New England Journal of Medicine has published a "Science behind the study" editorial on IB1001


Read the full announcement from IntraBio here:

Science Behind the Study Statement
.docx
Download DOCX • 15KB

NEJM Science Behind the Study
.pdf
Download PDF • 1.03MB

We are pleased to share that The New England Journal of Medicine (NEJM) has published a "Science Behind the Study” Expert Perspective Editorial on N-acetyl-L-leucine (IB1001) for the treatment of neurodegenerative diseases:


The Editorial reports the broad potential of IB1001 as a treatment of neurodegenerative diseases and recognises the applicability of IB1001 for the treatment of various neurodegenerative disorders, including all neurodegenerative lysosomal storage diseases, heritable cerebellar ataxias, and common disorders like traumatic brain injury.  

 

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:

23 views0 comments

Recent Posts

See All

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page